The global response to the COVID-19 pandemic has demonstrated the potential for innovation and science to overcome major health challenges and support a stronger society. As the UK Government has identified, there is now a unique opportunity for the country to become a global hub for life sciences investment over the next decade, helping the nation become healthier, wealthier and more resilient. Bristol Myers Squibb (BMS) commissioned PricewaterhouseCoopers (PwC) to develop the Life Sciences 2030 report to identify how best to achieve this goal.
The report is based on extensive research and the insights from dozens of experts from across the life sciences sector. It clearly identifies the capabilities the UK will need to secure its place as a life sciences superpower, and the health and economic impacts from achieving the vision for the UK.
To provide a better long-term view of the UK’s international competitiveness in life sciences and progress towards delivering on the Government’s aspirations for the sector as a global hub, PwC also worked with BMS to establish a Life Sciences 2030 Index. This combines multiple indicators to create a ranking of the relative performance of the UK in life sciences competitiveness against a number of comparator markets.
If you have any questions about our research, please do not hesitate to get in touch.
